Affinity maturation of humanized anti-epidermal growth factor receptor antibody using a modified phage-based open sandwich selection method

被引:4
|
作者
Sanada, Hideaki [1 ]
Kobayashi, Kazuki [1 ]
Oyama, Kenji [1 ]
Maru, Takamitsu [1 ]
Nakanishi, Takeshi [1 ]
Umetsu, Mitsuo [1 ]
Asano, Ryutaro [1 ,2 ]
Kumagai, Izumi [1 ]
机构
[1] Tohoku Univ, Grad Sch Engn, Dept Biomol Engn, Sendai, Miyagi 9808579, Japan
[2] Tokyo Univ Agr & Technol, Grad Sch Engn, Dept Biotechnol & Life Sci, Tokyo 1848588, Japan
来源
SCIENTIFIC REPORTS | 2018年 / 8卷
关键词
RESHAPING HUMAN-ANTIBODIES; BISPECIFIC ANTIBODY; THERMODYNAMIC CONSEQUENCES; CANCER-IMMUNOTHERAPY; MONOCLONAL-ANTIBODY; DISPLAY SYSTEM; DOMAIN ORDER; DIABODY; EGFR; STABILIZATION;
D O I
10.1038/s41598-018-23796-3
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Affinity maturation is one of the cardinal strategies for improving antibody function using in vitro evolutionary methods; one such well-established method is phage display. To minimise gene deletion, we previously developed an open sandwich (OS) method wherein selection was performed using only phage-displaying VH fragments after mixing with soluble VL fragments. The decrease in anti-EGFR antibody 528 affinity through humanization was successfully recovered by selecting VH mutants using this OS method. However, the affinity was not similar to that of parental 528. For further affinity maturation, we aimed to isolate VL mutants that act in synergy with VH mutants. However, the OS method could not be applied for selecting VL fragments because the preparation of soluble VH fragments was hampered by their instability and insolubility. Therefore, we initially designed a modified OS method based on domain-swapping of VH fragments, from added soluble Fv fragments to phagedisplaying VL fragments. Using this novel Fv-added OS selection method, we successfully isolated VL mutants, and one of the Fv comprising VH and VL mutants showed affinity almost equivalent to that of parental 528. This method is applicable for engineering other VL fragments for affinity maturation.
引用
收藏
页数:9
相关论文
共 45 条
  • [1] Development of an affinity-matured humanized anti-epidermal growth factor receptor antibody for cancer immunotherapy
    Nakanishi, Takeshi
    Maru, Takamitsu
    Tahara, Kazuhiro
    Sanada, Hideaki
    Umetsu, Mitsuo
    Asano, Ryutaro
    Kumagai, Izumi
    PROTEIN ENGINEERING DESIGN & SELECTION, 2013, 26 (02) : 113 - 122
  • [2] Anti-epidermal growth factor receptor-antibody therapy for treatment of breast cancer
    Solbach, C
    Roller, M
    Ahr, A
    Loibl, S
    Nicoletti, M
    Stegmueller, M
    Kreysch, HG
    Knecht, R
    Kaufmann, M
    INTERNATIONAL JOURNAL OF CANCER, 2002, 101 (04) : 390 - 394
  • [3] Hepatocellular carcinoma treated with anti-epidermal growth factor receptor antibody nimotuzumab A case report
    Song, Peng
    Yang, Jing
    Li, Xiaomei
    Huang, Haili
    Guo, Xueguang
    Zhou, Gang
    Xu, Xian
    Cai, Yi
    Zhu, Min
    Wang, Peng
    Zhao, Shu
    Zhang, Dong
    MEDICINE, 2017, 96 (39)
  • [4] Biomarkers for Predicting the Efficacy of Anti-Epidermal Growth Factor Receptor Antibody in the Treatment of Colorectal Cancer
    Okada, Yasuyuki
    Miyamoto, Hiroshi
    Goji, Takahiro
    Takayama, Tetsuji
    DIGESTION, 2014, 89 (01) : 18 - 23
  • [5] Internalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: A novel anti-epidermal growth factor receptor antibody
    Perera, Rushika M.
    Zoncu, Roberto
    Johns, Terrance G.
    Pypaert, Marc
    Lee, Fook-Thean
    Mellman, Ira
    Old, Lloyd J.
    Toomre, Derek K.
    Scott, Andrew M.
    NEOPLASIA, 2007, 9 (12): : 1099 - 1110
  • [6] A phase I study of an anti-epidermal growth factor receptor monoclonal antibody for the treatment of malignant gliomas
    Faillot, T
    Magdelenat, H
    Mady, E
    Stasiecki, P
    Fohanno, D
    Gropp, P
    Poisson, M
    Delattre, JY
    NEUROSURGERY, 1996, 39 (03) : 478 - 483
  • [7] Phase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors
    Wang, Chong
    He, Xiaohui
    Zhou, Bo
    Li, Jing
    Li, Bohua
    Qian, Weizhu
    Hou, Sheng
    Wang, Hao
    Shi, Yuankai
    Guo, Yajun
    MABS, 2011, 3 (01) : 67 - 75
  • [8] Structure and activity of an anti-epidermal growth factor receptor antibody without galactose-α-1,3-galactose residues
    Ren, Keyun
    Gong, Hao
    Ma, Zheng
    Tian, Lvming
    Ye, Wei
    Lv, Xingkai
    Wu, Chutse
    DRUG DEVELOPMENT RESEARCH, 2022, 83 (03) : 637 - 645
  • [9] Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme
    Eller, JL
    Longo, SL
    Hicklin, DJ
    Canute, GW
    NEUROSURGERY, 2002, 51 (04) : 1005 - 1013
  • [10] Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer
    Crombet, T
    Torres, L
    Neninger, E
    Catalá, M
    Solano, ME
    Perera, A
    Torres, O
    Iznaga, N
    Torres, F
    Pérez, R
    Lage, A
    JOURNAL OF IMMUNOTHERAPY, 2003, 26 (02) : 139 - 148